.jpg?sfvrsn=564980ad_1)
Jenny joined the firm’s dispute resolution team in 2016, having previously worked in-house at Actavis/Allergan, where she handled the high-profile pregabalin and tadalafil litigations. Jenny’s strong scientific background, which includes a doctorate in molecular and structural biology from the University of Oxford, together with her previous in-house experience, gives her an in-depth understanding of the life sciences sector from her clients’ perspectives.
Jenny has represented clients in contentious patent and SPC disputes up to the UK Supreme Court and the CJEU, concerning blockbuster small molecule drugs, therapeutic antibodies, enzyme replacement therapies, nanotechnology and orphan products.
Hugh Goodfellow, managing partner at Carpmaels & Ransford, commented: ‘Jenny is an outstanding litigator and all the partners very much look forward to the future with Jenny in the team. Her promotion will further strengthen our integrated dispute resolution capability and the holistic, strategic service we provide for our clients.’
